Three strategies for articulating a coherent product value story
Translating brilliant science into a reimbursable, commercially competitive product is a multidisciplinary challenge, not just a scientific one. Articulating a coherent product value story from the start of development can help companies raise funds from investors, make smarter development decisions, gain market share, and win reimbursement.
This article covers our top three strategies to prime your product for commercial success.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
Blog
Are unanchored matching-adjusted indirect comparisons a non-starter in EU Joint Clinical Assessments?
Jul 7, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Video
Bench-to-bedside: Transforming scientific breakthroughs into clinical success
Apr 3, 2026
CTB Blog
Even when capital flows freely, biotechs benefit from efficiency
Mar 24, 2026
CTB Blog
5 ways to secure biotech funding in 2026
Mar 19, 2026